Payment overview · 2025
General Payments
$687.32
34 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher Michael Street, MD
Allopathic & Osteopathic Physicians|Family Medicine · ASHEBORO, NC · NPI 1215375324
Verified facts
What the public records show
CMS Open Payments records show Christopher Michael Street, MD received $687.32 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.48 | 28.0% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $141.19 | 20.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.76 | 13.1% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.57 | 10.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.23 | 6.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.92 | 6.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.36 | 2.8% | 1 | 2025 |
| AYTU BioPharma, Inc. | Unresolved — no canonical attribution shown | $15.67 | 2.3% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $15.28 | 2.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.40 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.96 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.92 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.58 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $687.32 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $141.19 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.89 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.24 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.24 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $68.57 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.51 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.59 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Karbinal Normalized: karbinal |
Drug | AYTU BioPharma, Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 172 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 542 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 530 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 459 | 124 |
| Omeprazole | Omeprazole | 445 | 125 |
| Losartan Potassium | Losartan Potassium | 436 | 103 |
| Lisinopril | Lisinopril | 389 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 89 |
| Simvastatin | Simvastatin | 333 | 88 |
| Gabapentin | Gabapentin | 326 | 70 |
| Alprazolam | Alprazolam | 295 | 63 |
| Metformin Hcl | Metformin Hcl | 284 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 284 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 260 | 70 |
| Famotidine | Famotidine | 246 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 63 |
| Meloxicam | Meloxicam | 212 | 69 |
| Tramadol Hcl | Tramadol Hcl | 201 | 42 |
| Lorazepam | Lorazepam | 182 | 40 |
| Metformin Hcl Er | Metformin Hcl | 173 | 43 |
| Allopurinol | Allopurinol | 172 | 47 |
| Eliquis | Apixaban | 172 | 38 |
| Potassium Chloride | Potassium Chloride | 167 | 51 |
| Carvedilol | Carvedilol | 165 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 150 | 30 |
| Prednisone | Prednisone | 149 | 101 |
| Montelukast Sodium | Montelukast Sodium | 144 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 30 |
| Jardiance | Empagliflozin | 131 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 35 |
| Alendronate Sodium | Alendronate Sodium | 125 | 37 |
| Finasteride | Finasteride | 123 | 38 |
| Fluconazole | Fluconazole | 121 | 97 |
| Trazodone Hcl | Trazodone Hcl | 120 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 35 |
| Furosemide | Furosemide | 112 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 31 |
| Benazepril Hcl | Benazepril Hcl | 104 | 24 |
| Glimepiride | Glimepiride | 99 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 27 |
| Ezetimibe | Ezetimibe | 95 | 24 |
| Torsemide | Torsemide | 95 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 35 |
| Clonidine Hcl | Clonidine Hcl | 90 | 25 |
| Telmisartan | Telmisartan | 88 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 15 |
| Warfarin Sodium | Warfarin Sodium | 82 | suppressed |
| Bupropion Xl | Bupropion Hcl | 78 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 23 |
| Celecoxib | Celecoxib | 74 | 20 |
| Mupirocin | Mupirocin | 74 | 53 |
| Baclofen | Baclofen | 73 | 24 |
| Ozempic | Semaglutide | 73 | 17 |
| Cefdinir | Cefdinir | 69 | 59 |
| Atenolol | Atenolol | 68 | 16 |
| Farxiga | Dapagliflozin Propanediol | 67 | 16 |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 33 |
| Diazepam | Diazepam | 59 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 29 |
| Azithromycin | Azithromycin | 58 | 51 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 49 |
| Donepezil Hcl | Donepezil Hcl | 58 | 15 |
| Myrbetriq | Mirabegron | 57 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 13 |
| Ramipril | Ramipril | 57 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 17 |
| Chlorthalidone | Chlorthalidone | 49 | 14 |
| Glipizide Er | Glipizide | 49 | 11 |
| Nystatin | Nystatin | 49 | 22 |
| Enalapril Maleate | Enalapril Maleate | 47 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 46 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Mirtazapine | Mirtazapine | 46 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 14 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 12 |
| Spironolactone | Spironolactone | 44 | 12 |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 34 |
| Pregabalin | Pregabalin | 39 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Lovastatin | Lovastatin | 38 | 11 |
| Meclizine Hcl | Meclizine Hcl | 38 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 13 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 33 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Valsartan | Valsartan | 29 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Colchicine | Colchicine | 25 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | 11 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 14 |
| Primidone | Primidone | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 18 | 18 |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 11 |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $687.32 · 34 records | Novo Nordisk Inc | CAPVAXIVE, Doc Band, ELIQUIS, INSPIRE, KRYSTEXXA, Karbinal, Kerendia, Korlym, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error